{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Lipovite by Perdido Key Health And Wellness Inc
Source URL:
First approved in 2015
Source:
Lipovite by Perdido Key Health and Wellness Inc
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Targets:
L-METHIONINE-S,R-SULFOXIMINE is a convulsant, although the susceptibility to convulsions induced by this compound depends on the species, and primates are relatively resistant. It is a methionine sulfoximine in which the amino group has S-stereochemistry. It has a role as an EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor.
Sub-convulsive doses of L-METHIONINE-S,R-SULFOXIMINE are neuroprotective in rodent models of hyperammonemia, acute liver disease, and amyotrophic lateral sclerosis and suggest L-METHIONINE-S,R-SULFOXIMINE may be clinically useful. Studies have also indicated that L-METHIONINE-S,R-SULFOXIMINE is therapeutic in the treatment of glutamate excitotoxicity.
Status:
Possibly Marketed Outside US
Source:
21 CFR 358H
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 358H
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
NCT04609111: Phase 4 Interventional Active, not recruiting Acute Coronary Syndrome
(2021)
Source URL:
First approved in 2015
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Diaminohydroxypropane tetraacetic acid is a chelating agent for various metals including Fe, Mn, Tc and lanthanides.
Status:
Possibly Marketed Outside US
Source:
21 CFR 356
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 356
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 333C
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2018)
Source URL:
First approved in 2015
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
